Skip to main content
. 2021 Dec 9;37(2):273–284. doi: 10.1002/jbmr.4467

Fig. 1.

Fig. 1

Meta‐analysis of associations between sclerostin and cardiovascular disease risk factors, adjusted for age and ethnic group (ALSPAC) and sex (LURIC), body mass index, smoking, and social deprivation. (A) Sclerostin and risk of diabetes (figure shows odds ratio per SD increase in sclerostin with 95% confidence intervals [CI]); high fasting glucose; risk of hypertension; (B) sclerostin and eGFR (SD change in eGFR per SD increase in sclerostin, with 95% CI).